Compositions and methods for treating centrally mediated nausea and vomiting

A method of achieving no emesis during the overall phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly emetogenic chemotherapy, comprising a therapeutically effective amount of a. netupitant and b. palonosetron, or pharmaceutically acceptable salts thereof, wherein no emesis is obtained, as measured by no emetic episodes occurring within at least about 120 hours after the start of the moderately or highly emetogenic chemotherapy.

A method of achieving no emesis during the acute phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly emetogenic chemotherapy, comprising a therapeutically effective amount of a. netupitant and b. palonosetron, or pharmaceutically acceptable salts thereof, wherein no emesis is obtained, as measured by no emetic episodes occurring within at least about 24 hours after the start of the moderately or highly emetogenic chemotherapy.

A method of achieving no emesis during the delayed phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly emetogenic chemotherapy, comprising a therapeutically effective amount of a. netupitant and b. palonosetron, or pharmaceutically acceptable salts thereof, wherein no emesis is obtained, as measured by no emetic episodes occurring within at least about 24 to 120 hours after the start of the moderately or highly emetogenic chemotherapy.

A method of achieving no significant nausea during the overall phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly emetogenic chemotherapy, comprising a therapeutically effective amount of a. netupitant and b) palonosetron, or pharmaceutically acceptable salts thereof, wherein no significant nausea is obtained, as measured by a maximum VAS<25 mm within at least about 120 hours after the start of the moderately or highly emetogenic chemotherapy.

A method of achieving no significant nausea during the acute phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly emetogenic chemotherapy, comprising a therapeutically effective amount of a. netupitant and b) palonosetron, or pharmaceutically acceptable salts thereof, wherein no significant nausea is obtained, as measured by a maximum VAS<25 mm within at least about 24 hours after the start of the moderately or highly emetogenic chemotherapy.

A method of achieving no significant nausea during the delayed phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly emetogenic chemotherapy, comprising a therapeutically effective amount of a. netupitant and b) palonosetron, or pharmaceutically acceptable salts thereof, wherein no significant nausea is obtained, as measured by a maximum VAS<25 mm within at least about 24 to 120 hours after the start of the moderately or highly emetogenic chemotherapy.

A method of achieving no nausea during the delayed phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly emetogenic chemotherapy, comprising a therapeutically effective amount of a. netupitant and b. palonosetron, or pharmaceutically acceptable salts thereof, wherein no nausea is obtained, as measured by a maximum VAS<5 mm within at least about 24 to 120 hours after the start of the moderately or highly emetogenic chemotherapy.